4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Consensus Target Price of $28.90 According to Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given an average recommendation of “Moderate Buy” by the twelve research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $28.90.

A number of equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Cantor Fitzgerald upgraded shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 target price on the stock in a research note on Monday, September 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Thursday. The Goldman Sachs Group reaffirmed a “buy” rating and set a $32.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Finally, Bank of America lifted their price target on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, September 29th.

Insiders Place Their Bets

In related news, insider David Kirn sold 58,333 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $12.92, for a total transaction of $753,662.36. Following the transaction, the insider owned 709,153 shares in the company, valued at $9,162,256.76. This represents a 7.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 134,570 shares of company stock worth $1,759,323 in the last 90 days. 7.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of large investors have recently added to or reduced their stakes in FDMT. Toth Financial Advisory Corp purchased a new stake in 4D Molecular Therapeutics during the 3rd quarter valued at $29,000. Opaleye Management Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 197.8% during the 2nd quarter. Opaleye Management Inc. now owns 334,437 shares of the company’s stock valued at $4,448,000 after buying an additional 222,146 shares during the period. Engineers Gate Manager LP lifted its holdings in shares of 4D Molecular Therapeutics by 132.0% during the 2nd quarter. Engineers Gate Manager LP now owns 68,206 shares of the company’s stock valued at $907,000 after buying an additional 38,806 shares during the period. AXQ Capital LP purchased a new position in shares of 4D Molecular Therapeutics in the 2nd quarter worth $186,000. Finally, Headlands Technologies LLC boosted its stake in shares of 4D Molecular Therapeutics by 20.6% in the 2nd quarter. Headlands Technologies LLC now owns 19,238 shares of the company’s stock worth $256,000 after buying an additional 3,282 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Down 5.7%

FDMT stock opened at $12.14 on Tuesday. 4D Molecular Therapeutics has a 1-year low of $6.96 and a 1-year high of $16.93. The business has a fifty day moving average price of $14.00 and a 200-day moving average price of $11.51. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. The stock has a market capitalization of $670.61 million, a P/E ratio of -4.62 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The business had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. Equities analysts forecast that 4D Molecular Therapeutics will post -4.14 earnings per share for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.